Cardiac surgery

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

Retrieved on: 
Thursday, April 18, 2024
Health Technology, Clinical Trials, Teens, Cardiology, Parenting, Surgery, Biotechnology, Women, Children, Seniors, Other Science, Health, Research, Men, Family, Consumer, LGBTQ+, Science, Nursing, Medical Supplies, FDA, General Health, Medical Devices, Hospitals, Genetics, Society, Safety, Freezing, Atrial fibrillation, Workflow, LAA, Adolescence, Cardiac surgery, Intercostal nerves, Cryosphere, Pain management, Patient, Physician, Opioid, Temperature, Sympathetic nervous system, Medical college, Dentistry

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device.
  • The product is currently in an extended limited launch period in the United States, with full launch expected by the end of the second quarter.
  • “cryoSPHERE+ is a meaningful innovation that I believe will improve patient care, enhance outcomes, and enable physicians to perform procedures with greater ease and confidence,” said Michael Carrel, President and Chief Executive Officer at AtriCure.
  • Because of its long-lasting nature, physicians are adopting Cryo Nerve Block therapy using cryoSPHERE as part of their multi-modal pain management strategy.

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

Retrieved on: 
Wednesday, January 31, 2024
Hykes, Knowledge, Medtronic, Jan Vansina, Patient, Boston Scientific, MBA, Information system, Employment, CRM, University, Cardiac surgery, Hill-Rom, BBA, Management

Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors since 2022

Key Points: 
  • Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors since 2022
    MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc .
  • (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company’s new President and Chief Executive Officer, effective February 12.
  • Yared will retire from the Company and resign his Board seat concurrent with Hykes’ appointment and has agreed to consult with the Company to ensure a seamless transition.
  • Hykes currently serves as the President and CEO of Augmedics, a pioneer in augmented reality surgical navigation.

BC Platforms Appoints Dr. Ben Illigens as Chief Medical Officer

Retrieved on: 
Thursday, September 7, 2023
Real, Heart, Data science, Cardiac surgery, Health informatics, VP/CSS, Dakota Freie Presse, CMO, Research, Practice, Real world data, BCP, Harvard Medical School, Public sector, Doctor, Genomic and medical data, Clinical research, International University, Informatics, Drug discovery, Neurology, Biostatistics, HMS, Health, Medicine, Pharmaceutical industry, Nursing, Neuroscience

ZURICH, Switzerland, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BC Platforms (BCP), a global leader in healthcare data management and analytics, today announces the appointment of Dr. Ben M. W. Illigens, an experienced clinician and neuroscientist, as the company’s Chief Medical Officer.

Key Points: 
  • ZURICH, Switzerland, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BC Platforms (BCP), a global leader in healthcare data management and analytics, today announces the appointment of Dr. Ben M. W. Illigens, an experienced clinician and neuroscientist, as the company’s Chief Medical Officer.
  • Dr. Ben M. W. Illigens, newly appointed Chief Medical Officer at BC Platforms, commented on his appointment, “I am delighted to join the BC Platforms team.
  • I’ve long been fascinated by, and closely involved with, ways to optimize, accelerate, and innovate drug discovery and development using a data-driven, evidence-based, patient-centered approach.
  • He conducted clinical practice and research at HMS, and has over 60 peer-reviewed publications, including editing a core medical textbook on Clinical Research (1).

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

Retrieved on: 
Thursday, August 31, 2023
Blood pressure, Fresenius Medical Care, Critical care, Surgeon, Shock, ANVISA, Oxygen, Cardiac surgery, COVID-19, Cytokine adsorbing column, COVID, Inflammation, Septic shock, Marketing, Professional corporation, Sepsis, Patient, Cytosorbents Corporation, FMC, Nursing care plan, ICU, Brazilian Health Regulatory Agency, Death, Pharmaceutical industry, Hospital

PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb® was granted an expanded medical device registration by the Brazilian Health Regulatory Agency (ANVISA) to treat shock.

Key Points: 
  • PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb® was granted an expanded medical device registration by the Brazilian Health Regulatory Agency (ANVISA) to treat shock.
  • After receiving its first ANVISA registration in September 2020 to treat cytokine storm in cardiac surgery and critical illnesses such as COVID-19 in the midst of the COVID pandemic, CytoSorb has now received an expanded ANVISA registration to also include the treatment of shock – a common and frequently fatal complication of critical illness and cardiac surgery.
  • Mr. Alexandre Franco, Marketing Director of FMC Brazil, stated, “Fresenius Brazil is very proud of the registration approval of CytoSorb by ANVISA, which will help anchor our Critical Care portfolio.
  • We are pleased to commercialize CytoSorb in Brazil under this expanded registration through our partners FMC and Contatti Medical, both well-established and connected experts in their respective clinical fields.

Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System

Retrieved on: 
Wednesday, August 23, 2023
Surgeon, University, Clinical trial, Federal, Thoracic aortic aneurysm, Social Democratic Federation (United States), Penn Presbyterian Medical Center, Cardiopulmonary bypass, Silicon, Patient, Cardiac surgery, Risk, Principal, IDE, FDA, Dentistry

The procedure often requires 30-45 minutes of surgical time to complete anastomoses where the cardiothoracic surgeon sutures each individual native branch vessel to the surgical graft.

Key Points: 
  • The procedure often requires 30-45 minutes of surgical time to complete anastomoses where the cardiothoracic surgeon sutures each individual native branch vessel to the surgical graft.
  • The Duett Vascular Graft System was uniquely designed to standardize and simplify open surgical thoracic aortic procedures with the goal of providing cardiothoracic surgeons a means to treat the target vessels effectively and efficiently.
  • Dr. Szeto also highlighted his longstanding involvement with the Duett Vascular Graft System's evolution, since the company's inception, and expressed enthusiasm about participating in the imminent clinical trial.
  • "The Duett Vascular Graft System has been developed in collaboration with leading cardiothoracic surgeon and the device is aimed at helping to address the complexities and intricacies of thoracic aortic surgeries.

Dataintelo releases comprehensive Global Mobile C-arm Systems Market report providing valuable insights and growth factors

Retrieved on: 
Wednesday, June 21, 2023
Telecom, Media monitoring service, Prevalence, Health professional, Conditional sentence, Da Vinci Surgical System, Research, 2600-series (CTA), Midsayap Diagnostic Center and Hospital, Google Play, Mobile advertising, TA Telecom, MMS, Government, Multimedia Messaging Service, Service provider, Diagnosis, Travel, SMS, Hospital, Cancer, Entertainment, Code, Mobile Money, Bleeding, Small and medium enterprises in Mexico, Research report, Wilford Hall Ambulatory Surgical Center, Financial services, Cardiac surgery, Segment, Mobile web, Small, Location, Peripheral, Hospital Insurance and Diagnostic Services Act, Patient, BFSI, Education, Dentistry, Medical device, Online shopping, Others, Health care, Lithotripsy, Automotive industry, Growth, Neurosurgery, Insurance

This research report is a comprehensive analysis of the market trends, growth factors, and opportunities in the mobile C-arm systems industry.

Key Points: 
  • This research report is a comprehensive analysis of the market trends, growth factors, and opportunities in the mobile C-arm systems industry.
  • The Global Mobile C-arm Systems Market report is a meticulously crafted document that offers a detailed analysis of the market based on type, application, end user, and region.
  • One of the standout features of the report is its focus on the growth factors driving the global mobile C-arm systems market.
  • The Global Mobile C-arm Systems Market report by Dataintelo is a valuable resource for anyone interested in the market dynamics, trends, and growth factors.

Dataintelo releases comprehensive Global Mobile C-arm Systems Market report providing valuable insights and growth factors

Retrieved on: 
Wednesday, June 21, 2023
Telecom, Media monitoring service, Prevalence, Health professional, Conditional sentence, Da Vinci Surgical System, Research, 2600-series (CTA), Midsayap Diagnostic Center and Hospital, Google Play, Mobile advertising, TA Telecom, MMS, Government, Multimedia Messaging Service, Service provider, Diagnosis, Travel, SMS, Hospital, Cancer, Entertainment, Code, Mobile Money, Bleeding, Small and medium enterprises in Mexico, Research report, Wilford Hall Ambulatory Surgical Center, Financial services, Cardiac surgery, Segment, Mobile web, Small, Location, Peripheral, Hospital Insurance and Diagnostic Services Act, Patient, BFSI, Education, Dentistry, Medical device, Online shopping, Others, Health care, Lithotripsy, Automotive industry, Growth, Neurosurgery, Insurance

This research report is a comprehensive analysis of the market trends, growth factors, and opportunities in the mobile C-arm systems industry.

Key Points: 
  • This research report is a comprehensive analysis of the market trends, growth factors, and opportunities in the mobile C-arm systems industry.
  • The Global Mobile C-arm Systems Market report is a meticulously crafted document that offers a detailed analysis of the market based on type, application, end user, and region.
  • One of the standout features of the report is its focus on the growth factors driving the global mobile C-arm systems market.
  • The Global Mobile C-arm Systems Market report by Dataintelo is a valuable resource for anyone interested in the market dynamics, trends, and growth factors.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023
Telehealth, Medicine, Hospital, CV, EBIT, Interventional cardiology, Esaote, Cardiac catheterization, ECG, Medical imaging, Horvitz–Thompson estimator, Cardiology, CCU, Congress, MRI, Health, Magnetic resonance imaging, Acquisition, Cardiac surgery, Artificial intelligence, European Association for Cardio-Thoracic Surgery, ICU, Augment, PMI, Software, Echocardiography

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023
Telehealth, Medicine, Hospital, CV, EBIT, Interventional cardiology, Esaote, Cardiac catheterization, ECG, Medical imaging, Horvitz–Thompson estimator, Cardiology, CCU, Congress, MRI, Health, Magnetic resonance imaging, Acquisition, Cardiac surgery, Artificial intelligence, European Association for Cardio-Thoracic Surgery, ICU, Augment, PMI, Software, Echocardiography

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

Affluent Medical : Affluent Medical announces initial success of first clinical implantation of its Epygon mitral heart valve via minimally invasive route

Retrieved on: 
Thursday, March 16, 2023
Medtech, HCL, Urinary incontinence, Heart, Anatomy, Regulatory News Service, Mitral regurgitation, Cardiac rehabilitation, Hospital, Aix-en-Provence, Risk, Trial of the century, Pathology, Infarction, Death, Cardiac surgery, ISIN, Patient, Minerva, Science, Moyamoya disease, Mitral valve, Incidence, Princeton University Department of Psychology, Safety, Doctor of Philosophy, Rapids, Tricuspid valve, Diabetes, Proctor, Wealth, Medical device, Medical imaging, Dentistry, MD

Epygon is the only biomimetic mitral valve to restore the physiological blood vortex.

Key Points: 
  • Epygon is the only biomimetic mitral valve to restore the physiological blood vortex.
  • Rapid, 15 minutes, valve implantation procedure and early hospital discharge of the patient on day 5.
  • It is the only biomimetic cardiac mitral valve under development, mimicking the native mitral valve function and generating a physiological blood flow.
  • From initial hands-on the Epygon transcatheter device to deploying the valve inside the patient’s heart, it took me only 15 minutes.